Amiglyde-V (amikacin sulfate) Intrauterine Solution is an equine anti-infective that is indicated for the treatment of uterine infections (endometritis, metritis and pyometra) in mares, when caused by susceptible organisms including Escherichia coli, Pseudomonas spp. and Klebsiella spp. The use of AMIGLYDE-V in eliminating infections caused by the above organisms has been shown clinically to improve fertility in infected mares.
Amikacin injection is used to treat serious bacterial infections in many different parts of the body
Amiglyde-V has been shown to be effective for the treatment of uterine infections (endometritis, metritis and pyometra) in mares, when caused by susceptible organisms including Escherichia coli, Pseudomonas spp. and Klebsiella spp.
For treatment of uterine infections in mares, 2 grams (8 mL) of AMIGLYDE-V, mixed with 200mL 0.9% Sodium chloride injection, USP and aseptically infused into the uterus daily for three consecutive days, has been found to be the most efficacious dosage.
Consult with your veterinarian before use for exact dosing instructions.
Continuous use of aminoglycosides isn’t recommended because of the potential for additive effects.
IMPORTANT SAFETY INFORMATION: Concurrent use of other aminoglycosides should be avoided because of the potential for additive effects. Do not use AMIGLYDE-V in horses intended for human consumption. See full Prescribing Information.
– AMIGLYDE-V is nonirritating to equine endometrial tissue when infused into the uterus as directed (see Dosage and Administration). In laboratory animals as well as equine studies, the drug was generally found not to be irritating when injected intravenously, subcutaneously or intramuscularly.
– Although amikacin, like other aminoglycosides, is potentially nephrotoxic, ototoxic and neurotoxic, parenteral (intravenous) administration of AMIGLYDE-V twice daily at dosages of up to 10 mg/lb. for 15 consecutive days in horses resulted in no clinical, laboratory or histopathologic evidence of toxicity.
– Intrauterine infusion of 2 grams of AMIGLYDE-V eight hours prior to breeding by natural service did not impair fertility in mares. Therefore, mares should not be bred for at least eight hours following uterine infusion.
There are no known contraindications for the use of AMIGLYDE-V in horses other than a history of hypersensitivity to amikacin.
– Although AMIGLYDE-V is not absorbed to an appreciable extent following intrauterine infusion, concurrent use of other aminoglycosides should be avoided because of the potential additive effects.
– In vitro studies have demonstrated that when sperm are exposed to the preservative that is present in the 48 mL vials (250 mg/mL), sperm viability is impaired.
– Federal law restricts this drug to use by or on the order of a licensed veterinarian.
– Store at or below 25° C (77° F).
- – Use contents within three months of first vial puncture.